Empagliflozin; Metformin Hydrochloride Patent Expiration
Empagliflozin; Metformin Hydrochloride is Used for improving cardiovascular outcomes and managing type 2 diabetes, including in patients with renal impairment, by administering empagliflozin in combination with other medications. It was first introduced by Boehringer Ingelheim Pharmaceuticals Inc
Empagliflozin; Metformin Hydrochloride Patents
Given below is the list of patents protecting Empagliflozin; Metformin Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Synjardy Xr |
US9949998 (Pediatric) | Pharmaceutical composition, methods for treating and uses thereof | Dec 11, 2034 | Boehringer Ingelheim |
| Synjardy |
US9949997 (Pediatric) | Pharmaceutical composition, methods for treating and uses thereof | Nov 17, 2034 | Boehringer Ingelheim |
| Synjardy Xr |
US9949997 (Pediatric) | Pharmaceutical composition, methods for treating and uses thereof | Nov 17, 2034 | Boehringer Ingelheim |
| Synjardy |
US10258637 (Pediatric) | Pharmaceutical composition, methods for treating and uses thereof | Oct 03, 2034 | Boehringer Ingelheim |
| Synjardy |
US11090323 (Pediatric) | Pharmaceutical composition, methods for treating and uses thereof | Oct 03, 2034 | Boehringer Ingelheim |
| Synjardy Xr |
US10258637 (Pediatric) | Pharmaceutical composition, methods for treating and uses thereof | Oct 03, 2034 | Boehringer Ingelheim |
| Synjardy Xr |
US11090323 (Pediatric) | Pharmaceutical composition, methods for treating and uses thereof | Oct 03, 2034 | Boehringer Ingelheim |
| Synjardy Xr | US9949998 | Pharmaceutical composition, methods for treating and uses thereof | Jun 11, 2034 | Boehringer Ingelheim |
| Synjardy | US9949997 | Pharmaceutical composition, methods for treating and uses thereof | May 17, 2034 | Boehringer Ingelheim |
| Synjardy Xr | US9949997 | Pharmaceutical composition, methods for treating and uses thereof | May 17, 2034 | Boehringer Ingelheim |
| Synjardy | US10258637 | Pharmaceutical composition, methods for treating and uses thereof | Apr 03, 2034 | Boehringer Ingelheim |
| Synjardy | US11090323 | Pharmaceutical composition, methods for treating and uses thereof | Apr 03, 2034 | Boehringer Ingelheim |
| Synjardy | US11813275 | Pharmaceutical composition, methods for treating and uses thereof | Apr 03, 2034 | Boehringer Ingelheim |
| Synjardy | US11833166 | Pharmaceutical composition, methods for treating and uses thereof | Apr 03, 2034 | Boehringer Ingelheim |
| Synjardy Xr | US10258637 | Pharmaceutical composition, methods for treating and uses thereof | Apr 03, 2034 | Boehringer Ingelheim |
| Synjardy Xr | US11090323 | Pharmaceutical composition, methods for treating and uses thereof | Apr 03, 2034 | Boehringer Ingelheim |
| Synjardy Xr | US11813275 | Pharmaceutical composition, methods for treating and uses thereof | Apr 03, 2034 | Boehringer Ingelheim |
| Synjardy Xr | US11833166 | Pharmaceutical composition, methods for treating and uses thereof | Apr 03, 2034 | Boehringer Ingelheim |
| Synjardy Xr |
US10596120 (Pediatric) | Pharmaceutical compositions | Sep 07, 2032 | Boehringer Ingelheim |
| Synjardy Xr | US10596120 | Pharmaceutical compositions | Mar 07, 2032 | Boehringer Ingelheim |
| Synjardy |
US10610489 (Pediatric) | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof | Mar 30, 2031 | Boehringer Ingelheim |
| Synjardy | US10610489 | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof | Sep 30, 2030 | Boehringer Ingelheim |
| Synjardy | US12115179 | Pharmaceutical composition, methods for treating and uses thereof | Feb 11, 2030 | Boehringer Ingelheim |
| Synjardy Xr | US12115179 | Pharmaceutical composition, methods for treating and uses thereof | Feb 11, 2030 | Boehringer Ingelheim |
| Synjardy |
US7579449 (Pediatric) | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture | Feb 01, 2029 | Boehringer Ingelheim |
| Synjardy Xr |
US7579449 (Pediatric) | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture | Feb 01, 2029 | Boehringer Ingelheim |
| Synjardy | US7579449 | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture | Aug 01, 2028 | Boehringer Ingelheim |
| Synjardy Xr | US7579449 | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture | Aug 01, 2028 | Boehringer Ingelheim |
| Synjardy |
US7713938 (Pediatric) | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments | Oct 15, 2027 | Boehringer Ingelheim |
| Synjardy Xr |
US7713938 (Pediatric) | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments | Oct 15, 2027 | Boehringer Ingelheim |
| Synjardy | US7713938 | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments | Apr 15, 2027 | Boehringer Ingelheim |
| Synjardy Xr | US7713938 | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments | Apr 15, 2027 | Boehringer Ingelheim |
| Synjardy Xr | US6488962 | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
Jun 20, 2020
(Expired) | Boehringer Ingelheim |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Empagliflozin; Metformin Hydrochloride's patents.
Latest Legal Activities on Empagliflozin; Metformin Hydrochloride's Patents
Given below is the list recent legal activities going on the following patents of Empagliflozin; Metformin Hydrochloride.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 27 Sep, 2023 | US10610489 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 13 Sep, 2023 | US10596120 |
| Recordation of Patent Grant Mailed Critical | 07 Apr, 2020 | US10610489 |
| Patent Issue Date Used in PTA Calculation Critical | 07 Apr, 2020 | US10610489 |
| Recordation of Patent Grant Mailed Critical | 24 Mar, 2020 | US10596120 |
| Patent Issue Date Used in PTA Calculation Critical | 24 Mar, 2020 | US10596120 |
| Email Notification Critical | 19 Mar, 2020 | US10610489 |
| Issue Notification Mailed Critical | 18 Mar, 2020 | US10610489 |
| Correspondence Address Change Critical | 12 Mar, 2020 | US10596120 |
| Dispatch to FDC | 05 Mar, 2020 | US10610489 |
Empagliflozin; Metformin Hydrochloride's Family Patents
Explore Our Curated Drug Screens
Empagliflozin; Metformin Hydrochloride Generic API Manufacturers
Several generic applications have been filed for Empagliflozin; Metformin Hydrochloride.
Given below is the list of companies who have filed for Empagliflozin; Metformin Hydrochloride generic, along with the locations of their manufacturing plants worldwide.
1. ZYDUS PHARMS
Zydus Pharmaceuticals Usa Inc has filed for 4 different strengths of generic version for Empagliflozin; Metformin Hydrochloride. All of these versions come by the name EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE. Given below are the details of the strengths of this generic introduced by Zydus Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 5MG; 500MG | tablet | Discontinued | ORAL | N/A | Jul 7, 2022 |
| 5MG; 1GM | tablet | Discontinued | ORAL | N/A | Jul 7, 2022 |
| 12.5MG; 500MG | tablet | Discontinued | ORAL | N/A | Jul 7, 2022 |
| 12.5MG; 1GM | tablet | Discontinued | ORAL | N/A | Jul 7, 2022 |